Key result
Proton-pump inhibitor prophylaxis during antiplatelet therapy reduces the risk of upper gastrointestinal bleeding.
Why the study?
How should gastrointestinal bleeding be managed and prevented in patients receiving antiplatelet therapy?
How should gastrointestinal bleeding be managed and prevented in patients receiving antiplatelet therapy?
This review highlights the importance of PPI prophylaxis to prevent GI bleeding and the early resumption of antiplatelet therapy after hemostasis to prevent ischemic events.
Answers are grounded in this paper and cite their sources.
May support immediate antiplatelet resumption after GI hemostasis; leaves open need for randomized confirmation in high-risk patients.
Antiplatelet therapy is the standard of care for the secondary prevention of acute coronary syndrome and ischemic stroke, especially after coronary intervention. However, this therapy is associated with bleeding complications such as gastrointestinal bleeding, which is one of the most common life-threatening complications. Early endoscopy is recommended for most patients with acute upper gastrointestinal bleeding. After successful endoscopic hemostasis, immediate resumption of antiplatelet therapy with proton-pump inhibitors (PPIs) is recommended to prevent further ischemic events. PPI prophylaxis during antiplatelet therapy reduces the risk of upper gastrointestinal bleeding. The potential negative metabolic interaction between PPIs and clopidogrel is still unclear.
No takes yet. Share an insight, caveat, or question.
Hiroshi Yasuda (2015) conducted a review in Gastrointestinal bleeding in patients receiving antiplatelet therapy. Proton-pump inhibitors (PPIs) was evaluated. Proton-pump inhibitor prophylaxis during antiplatelet therapy reduces the risk of upper gastrointestinal bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: